Zealand Pharma AS (fra:22Z) Share Price

Company Profile

Business description
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
Contact
Sydmarken 11
SoborgDK-2860
DNK
T: +45 88773600
E: [email protected]
https://www.zealandpharma.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
578

Recommended

We see regulatory risk from both the US and Chinese governments.

Seth Goldstein, CFA | 25 October 2026

Near-term pain, long-term potential.

Dan Baker | 22 October 2026

We see the company’s momentum in its core advertising business, as well as adoption of Muse, as early signals that the firm’s AI playbook is working.

Malik Ahmed Khan, CFA | 22 October 2026

Index	Last price	Change	% Change
All Ordinaries	8,926.60	20.80	0.23%
CAC 40	7,842.18	59.36	0.76%
DAX 40	25,413.50	231.85	0.92%
Dow JONES (US)	52,215.16	652.82	-1.23%
FTSE 100	10,730.93	40.57	0.38%
HKSE	23,211.81	118.44	0.51%
NASDAQ	25,955.34	53.52	-0.21%
Nikkei 225	62,189.65	503.51	-0.80%
NZX 50 Index	13,733.93	12.91	-0.09%
S&P 500	7,623.68	39.75	-0.52%
S&P/ASX 200	8,809.90	14.70	0.17%
SSE Composite Index	3,697.52	7.04	0.19%